AstraZeneca Looks To Muscle In On BMS-Dominated Neoadjuvant NSCLC Setting
Executive Summary
Without disclosing data, the company reported positive pathological complete response data from the AEGEAN study of its PD-L1 inhibitor Imfinzi in neoadjuvant NSCLC, where BMS’s Opdivo won approval in March.
You may also be interested in...
Innate Lead Candidate Fails In Head And Neck Cancer But Partner AZ Offers Hope In NSCLC
Innate’s lead candidate has reached the end of the road in head and neck carcinoma after a disappointing interim Phase III trial analysis but hope remains that a combination with partner AstraZeneca's Imfinzi could succeed elsewhere.
Can’t Win Them All: Two Merck Oncology Trials Fail
The company stopped a study of Lynparza in colorectal cancer for futility and announced a study of Keytruda/chemoradiation in head-and-neck cancer didn’t meet its primary endpoint.